Clinical Trial

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

Study acronym: IN-DXM-EMRR
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated February 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-15.
Trial Details
NCT Number NCT06223074
Lead Sponsor Universidad Nacional Autonoma de Mexico
Collaborators: Instituto Nacional de Neurología y Neurocirugía
Conditions Multiple Sclerosis Relapsing Remitting, Treatment
Enrollment 80 participants
Start Date 2023-01-09
Primary Completion 2026-02-25 (estimated)
Study Completion 2026-07-05 (estimated)
Updated on ClinicalTrials.gov 2025-04-03